Advertisements


ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance. ResMed Inc.'s RMD adjusted earnings per share (EPS) in the fourth quarter of fiscal 2022 were $1.49, up 10.4% year over year. The metric also surpassed the Zacks Consensus Estimate by 0.7%.The adjustments include certain non-recurring expenses/benefits like amortization of acquired intangibles and restructuring costs, among others.Full-year adjusted EPS was $5.79, up 8.6%. The metric surpassed the Zacks Consensus Estimate by 0.7%.GAAP EPS in the reported quarter was $1.33, similar to the year-ago quarter’s EPS.RevenuesFiscal fourth-quarter revenues on a reported basis increased 4.4% year over year (up 8% at constant exchange rate or CER) to $914.7 million. However, the figure beat the Zacks Consensus Estimate by 0.3%.In fiscal 2022, revenues increased 11.9% to $3.58 billion. The metric was in line with Zacks Consensus Estimate.A Closer View of Q2 Top LineTotal Sleep and Respiratory Care revenues in the United States, Canada and Latin America improved 11.9% from the prior-year period to $528.5 million.Total Sleep and Respiratory Care revenues in Europe, Asia and other markets fell 8.1% on a reported basis and rose 1% at CER to $283.1 million.Global revenues from total Sleep and Respiratory Care in the quarter under review were $811.6 million, up 4% on a reported basis and 8% at CER.ResMed Inc. Price, Consensus and EPS Surprise ResMed Inc. price-consensus-eps-surprise-chart | ResMed Inc. QuoteMeanwhile, Software as a Service (SaaS) revenues grew 7.6% to $103.1 million.The revenue growth in the quarter was due to increased demand for ResMed’s sleep and respiratory care devices, driven by a steady recovery of markets and greater device demand in response to a competitor’s ongoing product recall. The upside in SaaS revenues resulted from continued growth across the company’s portfolio of verticals, including home medical equipment and facilities-based and home-based care settings.MarginsAdjusted gross profit in the quarter under review rose 5.4% to $528.9 million despite a 3.1% uptick in the cost of sales (excluding expenses related to amortization of acquired intangibles and restructuring).Adjusted gross margin for the fiscal fourth quarter was 57.8%, reflecting a 55-basis point (bps) expansion, primarily owing to an improvement in average selling prices and favorable product mix changes. However, this was partially offset by higher freight and manufacturing costs and unfavorable geographic mix changes.Selling, general and administrative expenses rose 7.4% year over year to $194.9 million (up 12% at CER) predominantly on increases in employee-related expenses, professional service fees and travel expenses. Research and development expenses increased 7.4% to $64.3 million (up 11% at CER).Adjusted operating income was $269.7 million in the quarter under discussion, up 3.6% from the year-ago quarter. Adjusted operating margin contracted 24 bps year over year to 29.5%.Financial UpdatesResMed exited the fourth quarter of fiscal 2022 with cash and cash equivalents of $201.8 million compared with $273.7 million at the end of the fiscal third quarter. Total debt (short and long-term) at the end of the fiscal fourth quarter was $775.2 million compared with $655.4 million a year ago.Cumulative net cash provided by operating activities at the end of the fiscal fourth quarter was $351.1million, compared with a cumulative net cash inflow of $736.7million in the year-ago quarter.    The company paid out $61.5 million as dividends during the fiscal fourth quarter.Our TakeResMed exited the fourth quarter of fiscal 2022 with better-than-expected earnings and revenues. The company recorded robust sales performance in the quarter on increased demand for sleep and respiratory care devices. Robust revenue growth across several geographies is encouraging. The growing adoption of ResMed’s AirSense 11 and AirSense 10 platforms raises investors’ confidence. Expansion of gross margin seems promising.However, the company did not derive any incremental revenue from COVID-19-related demand in the fiscal fourth quarter compared with the year-ago period’s levels. Contraction of operating margin on escalating expenses is discouraging. The persistent supply chain constraints in a challenging freight environment are hampering ResMed’s ability to meet the growing device demand.Zacks Rank and Key PicksResMed currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space that have announced quarterly results are Quest Diagnostics Inc. DGX, Molina Healthcare, Inc. MOH and Merck & Co. MRK.Quest Diagnostics, carrying a Zacks Rank #2 (Buy), reported second-quarter 2022 adjusted EPS of $2.36, which beat the Zacks Consensus Estimate by 9.8%. Revenues of $2.45 billion outpaced the consensus mark by 7.5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Quest Diagnostics has an earnings yield of 6.9% compared with the industry’s 3.9%. DGX’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average being 12.1%.Molina Healthcare, having a Zacks Rank #2, reported second-quarter 2022 adjusted EPS of $4.55, which beat the Zacks Consensus Estimate by 4.8%. Revenues of $8.1 billion outpaced the consensus mark by 6.2%.Molina Healthcare has a long-term estimated growth rate of 16.4%. MOH’s earnings surpassed estimates in the trailing four quarters, the average being 3.2%.Merck reported second-quarter 2022 adjusted earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.67. Revenues of $14.6 billion surpassed the Zacks Consensus Estimate by 5.4%. It currently has a Zacks Rank #2.Merck has a long-term estimated growth rate of 10.1%. MRK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 16.8%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report ResMed Inc. (RMD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Time to Buy These Giant Tech Stocks as the Nasdaq Enters a Bull Market?

The episode explores three stocks that operate in the broader world of technology--Adobe, Mastercard, and Microsoft--that run businesses poised to hold up well during the current economic slowdown and thrive for years to come. Today’s episode of Full Court Finance at Zacks dives into some of the reasons why the technology-heavy Nasdaq entered a bull market, with it up over 20% from its mid-June lows. The episode then explores three stocks that operate in the broader world of technology—Adobe, Mastercard, and Microsoft—that run businesses poised to hold up well during the current economic slowdown and thrive for years to come.The July consumer price index report was the big event on Wall Street during the week of August 8. Some investors latched onto the fact that prices came in flat compared to June. And July’s 8.5% CPI figure came in below June’s 9.1% annual climb.Wall Street responded by sending the Nasdaq soaring nearly 3% Wednesday following the CPI release to push it over the bull market threshold of a 20% climb off its lows. The recent market positivity might suggest investors are pricing in a continued decline in oil and gas, as well as significantly lower consumer spending that would be needed to bring inflation down.The S&P 500 has also climbed over 16% during this same stretch. With the larger climbs, of course, following the market’s worst first-half since 1970. The run since the mid-June lows crucially coincided with sliding 10-year U.S. Treasury yields, which are hovering around 2.85% on Friday vs. their 3.5% peaks. Lower interest rates boost stock prices. The other key factor that determines stock prices, earnings, held up well in Q2.The backdrop might leave investors wondering if it’s time to buy some of the mega-cap technology stocks that are helping drive the broader market comeback. The first stock up on the list today is credit card power Mastercard MA.Mastercard is expanding and diversifying beyond its traditional credit card segment and is prepared to thrive in an increasingly cashless and digital payment-based economy. Mastercard topped Zacks Q2 projections on July 28 and provided solid guidance in the face of mounting worries about a slowing economy. MA lands a Zacks Rank #2 (Buy) at the moment and it trades 20% below its current Zacks consensus price target.Changing gears, Adobe ADBE and its subscription-based creative and design software have become the backbone of tons of art and media. Adobe’s various offerings are utilized by Hollywood studios, global advertising agencies, college students, and beyond. ADBE’s guidance came in a bit lower than projected, but it still marks what would be the continuation of an impressive streak of top and bottom-line growth.The last stock up today is Microsoft MSFT. The company was one of the first to warn Wall Street about the negative impacts the strong U.S. dollar would have on its top and bottom lines. Microsoft did fall short of our Q4 FY22 ESP estimates on July 26. But even with its slightly downbeat guidance, MSFT’s outlook showcases the power and impact its growing portfolio has throughout the global economy, from cloud computing on down the line. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT): Free Stock Analysis Report Mastercard Incorporated (MA): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Walmart Q2 Preview: Rebound Quarter Inbound?

Walmart missed the Zacks Consensus EPS Estimate by 11% in its latest quarter. The Zacks Retail and Wholesale Sector has struggled year-to-date, but over the last month, it’s outperformed the S&P 500, penciling in a solid 12% gain. Below is a table illustrating the sector’s performance vs. the S&P 500 over several timeframes.Image Source: Zacks Investment ResearchA titan residing in the sector, Walmart WMT, is on deck to reveal Q2 results on Tuesday, August 16th, after market close.Walmart is a massive retailer, with its product offering ranging from grocery to cosmetics, electronics to stationery, home furnishings to health and wellness products, and apparel to entertainment products, to name a few.We see their stores at seemingly every turn. How does the retail giant stack up heading into its quarterly print? Let’s take a closer look.Share Performance & ValuationWalmart shares have outperformed the S&P 500 by a respectable margin year-to-date, but are still down nearly 9%.Image Source: Zacks Investment ResearchHowever, over the last month, WMT shares have lagged the general market, tacking on 5% in value vs. the S&P 500’s gain of nearly 11%.Image Source: Zacks Investment ResearchIn addition, Walmart shares carry relatively strong valuation levels. The company’s 22.9X forward earnings multiple is just a tick above its five-year median of 22.6X and represents an enticing 14% discount relative to its Zacks Sector.Image Source: Zacks Investment ResearchQuarterly EstimatesAnalysts have been overwhelmingly bearish for the quarter-to-be reported, with 12 downwards estimate revisions coming in over the last 60 days with a 100% revision agreement. The Zacks Consensus EPS Estimate resides at $1.60, reflecting a 10% decrease in quarterly earnings year-over-year.Image Source: Zacks Investment ResearchStill, Walmart’s top-line looks to register solid growth – WMT is forecasted to have generated a mighty $151 billion in revenue throughout the quarter, penciling in a substantial 7% year-over-year uptick.Quarterly Performance & Market Reactions The retail titan has consistently reported bottom-line results above the Zacks Consensus EPS Estimate, with seven bottom-line beats over its last ten quarters. However, in its latest quarter, WMT recorded a disheartening 11% EPS miss.Top-line results have been remarkable – Walmart has chained together nine consecutive revenue beats. Below is a chart illustrating the company’s revenue on a quarterly basis.Image Source: Zacks Investment ResearchIn addition, the market has primarily acted poorly to the company’s earnings releases, with shares moving down following four of its previous six quarterly prints.Putting Everything TogetherWalmart shares have been notably defensive throughout 2022, but over the last month, shares have lagged the general market. In addition, valuation levels are relatively sound compared to its sector.Analysts have been very bearish for the quarter to be reported, and the company’s bottom-line is forecasted to take a deep hit, a reflection of rising costs eating deep into margins. However, WMT’s top-line is forecasted to register solid growth.Furthermore, Walmart has consistently reported quarterly results above estimates.Heading into the print, Walmart WMT carries a Zacks Rank #4 (Sell) with an overall VGM Score of a C. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walmart Inc. (WMT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Top Stock Reports for Eli Lilly, CVS Health & Target

Today's Research Daily features new research reports on 12 major stocks, including Eli Lilly and Company (LLY), CVS Health Corporation (CVS), and Target Corporation (TGT) Friday, August 12, 2022The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Eli Lilly and Co. (LLY), CVS Health Corp. (CVS) and Target Corp. (TGT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+15.5% vs. +6.5%). The company boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Its revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others.Eli Lilly is regularly adding promising new pipeline assets through business development deals. Lilly expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease. Both drugs have multibillion dollar sales potential.However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.(You can read the full research report on Eli Lilly here >>>)CVS Health’s shares have outperformed the Zacks Retail - Pharmacies and Drug Stores industry over the past year (+26.6% vs. +11.9%). The company’s robust sales growth across all three operating segments drove the top-line results. The extended cough, cold and flu season boosted sales in the Retail and Pharmacy businesses.Within the Health Care Benefits arm, the continued growth across the entire range of insured and self-insured medical, pharmacy, dental and behavioral health products and services instills optimism. The raised EPS guidance for 2022 is indicative of this growth momentum continuing.However, the contraction of margins does not bode well. The decline in COVID-19 vaccinations and testing sales is a downside. Persistent pharmacy reimbursement headwinds also continued to impact business results.(You can read the full research report on CVS Health here >>>)Target’s shares have declined -25.2% over the year-to-date basis against the Zacks Retail - Discount Stores industry’s decline of -10.3%. The company’s operating margin rate is in a range of around 6% and it anticipates a low-to-mid-single digit revenue growth forecast for fiscal 2022.However, deploying resources to enhance omnichannel capabilities, come up with new brands, refurbish stores and expand same-day delivery options to provide customers a seamless shopping experience. The company has been making multiple changes to its business model to adapt and stay relevant in the ever-evolving retail landscape. These have been contributing to the company’s sales performance.Also, its recent attempt to right-size inventory is a step in the right direction, as the demand skewed toward consumer staples and away from discretionary categories. This may hurt margins for now but will help better the position for the company to gain market share.(You can read the full research report on Target here >>>)Other noteworthy reports we are featuring today include Equinix, Inc. (EQIX), Chipotle Mexican Grill, Inc. (CMG), and FirstEnergy Corp. (FE).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadLilly (LLY) Potential New Products Key to GrowthRobust Pharmacy Sales Aid CVS Health (CVS) Amid Rising CostsTarget's (TGT) Omnichannel Efforts, Digitization to Aid SalesFeatured ReportsExpansion Strategy Aids Equinix (EQIX) Amid Stiff CompetitionPer the Zacks Analyst, acquisitions will expand Equinix's data-center footprint and enhance inter-connection offerings. However, stiff competition might unfavorably impact its pricing power.Chipotle (CMG) Banks on Digital Sales, Wage Inflation HighPer the Zacks analyst, digitalization will continue to play a crucial role in sustaining growth for restaurant operators. However, elevated wage inflation is a concern.Infrastructure Investment, Clean Assets Aid FirstEnergy (FE)Per the Zacks analyst, FirstEnergy's investment of $17 billion through 2025 to enhance clean electricity generation and strengthen its infrastructure will boost its profitability.End-Market Demand Aids Xylem (XYL) Amid Supply-Chain WoesPer the Zacks analyst, solid global demand across end markets, robust backlogs and orders are supporting Xylem's growth, despite supply-chain constraints, raw material and labor cost inflation.NetApp (NTAP) Benefits from Product Portfolio & AcquisitionsPer the Zacks analyst, NetApp's performance is gaining from continued strength in Hybrid Cloud and Public Cloud segments and robust billings growth. Synergies from recent acquisitions also bode well.New UpgradesNOV Inc. (NOV) to Benefit from Large Installed Base of RigsThe Zacks analyst believes that NOV's large installed base of rigs worldwide will provide a steady recurring revenue stream driven by demand for maintenance, parts and other expendable products.Upbeat Air-Travel Demand Aids SkyWest (SKYW), High Costs AilImproved air-travel demand is driving SkyWest's top line. The Zacks analyst is, however, worried about escalated fuel costs that are limiting bottom-line growth.New DowngradesRising Payroll Expense to Hurt Dillard's (DDS) Gross MarginPer the Zacks analyst, Dillard's has been witnessing higher payroll and payroll-related expenses amid the current competitive wage environment. This along with inflation are likely to persist in FY22.Escalating Expenses, High Debt Hurt Encompass Health (EHC)Per the Zacks analyst, the company's rising labor cost continues to squeeze margins. A leveraged balance sheet constantly affects its financial flexibility. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Equinix, Inc. (EQIX): Free Stock Analysis Report FirstEnergy Corporation (FE): Free Stock Analysis Report Target Corporation (TGT): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Agilent Technologies Q3 Preview: Can the Earnings Streak Continue?

The company has been on a blazing-hot earnings streak, chaining together nine consecutive bottom-line beats. The Zacks Computer and Technology sector has been notably strong over the last month, increasing more than 10% in value and outperforming the S&P 500. Still, the sector is deep in the red year-to-date.Below is a table illustrating the sector’s performance vs. the S&P 500 over several timeframes.Image Source: Zacks Investment ResearchA company residing in the sector that sports the highly-coveted single letter ticker, Agilent Technologies A, is on deck to reveal Q3 results after market close on Tuesday, August 16th.Agilent Technologies is an original equipment manufacturer (OEM) of a broad-based portfolio of test and measurement products serving multiple end markets. The company was originally a spin-off from Hewlett-Packard.How does the company stack up heading into the quarterly print? Let’s dive in and find out.Share Performance & ValuationYear-to-date, Agilent shares have been notably stronger than its Zacks Sector but are still down 16%.Image Source: Zacks Investment ResearchOver the last month, Agilent shares have soared, tacking on an impressive 12% double-digit gain and just barely outperforming its Zacks Sector.Image Source: Zacks Investment ResearchThe recent strong price action is undoubtedly a positive, signaling that buyers have finally reappeared.Pivoting to valuation, A’s forward earnings multiple of 27.1X is marginally above its five-year median of 26.4X and represents a somewhat steep 10% premium relative to its sector.Image Source: Zacks Investment ResearchQuarterly Estimates Two analysts have lowered their earnings outlook for the quarter over the last 60 days, with the Consensus Estimate Trend slipping marginally. Still, the $1.20 Zacks Consensus EPS Estimate pencils in a solid 9% year-over-year uptick in earnings.Image Source: Zacks Investment ResearchAgilent’s top-line looks to register solid growth as well – the company is projected to have generated $1.6 billion in revenue throughout the quarter, good enough for a 3% year-over-year uptick.Quarterly Performance & Market Reactions A’s been on a blazing-hot earnings streak, chaining together nine consecutive bottom-line beats. In just its latest quarter, the company recorded a marginal 2% EPS beat.Top-line results have also been remarkable – A has penciled in nine revenue beats over its last ten quarters. Below is a chart illustrating the company’s revenue on a quarterly basis.Image Source: Zacks Investment ResearchIn addition, day-traders should be aware that following each of its last three quarterly prints, shares have moved downwards each time, all by at least 4.5%.Putting Everything TogetherAgilent shares have been hot as of late, outperforming its Zacks Sector over the last month and year-to-date. Valuation levels appear slightly elevated, with shares trading above their five-year median and its Zacks Sector average.Analysts have been bearish for the quarter, but the company is projected to register solid top and bottom-line growth.Furthermore, A has consistently reported quarterly results above expectations, but the market hasn’t reacted well following the releases as of late.Heading into the print, Agilent Technologies A carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of -1.8%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates

Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? Humanigen Inc. (HGEN) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $1.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.47%. A quarter ago, it was expected that this company would post a loss of $0.49 per share when it actually produced a loss of $0.32, delivering a surprise of 34.69%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Humanigen Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.04 million for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.39%. This compares to year-ago revenues of $1.04 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Humanigen Inc. Shares have lost about 90% since the beginning of the year versus the S&P 500's decline of -11.7%.What's Next for Humanigen Inc.While Humanigen Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Humanigen Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.24 on $1.04 million in revenues for the coming quarter and -$1.15 on $2.6 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.BeyondSpring Inc. (BYSI), another stock in the same industry, has yet to report results for the quarter ended June 2022.This company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +51%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.BeyondSpring Inc.'s revenues are expected to be $0.3 million, down 11.8% from the year-ago quarter. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humanigen Inc. (HGEN): Free Stock Analysis Report BeyondSpring Inc. (BYSI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Beam Global (BEEM) Reports Q2 Loss, Tops Revenue Estimates

Beam Global (BEEM) delivered earnings and revenue surprises of -47.37% and 17.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? Beam Global (BEEM) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -47.37%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.24, delivering a surprise of -33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Beam Global, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $3.72 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 17.14%. This compares to year-ago revenues of $2.12 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Beam Global shares have lost about 14.7% since the beginning of the year versus the S&P 500's decline of -11.7%.What's Next for Beam Global?While Beam Global has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Beam Global: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $4.68 million in revenues for the coming quarter and -$0.68 on $18.08 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the bottom 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Another stock from the same industry, Arcimoto, Inc. (FUV), has yet to report results for the quarter ended June 2022. The results are expected to be released on August 15.This company is expected to post quarterly loss of $0.33 per share in its upcoming report, which represents a year-over-year change of -43.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.Arcimoto, Inc.'s revenues are expected to be $1.4 million, up 94.4% from the year-ago quarter. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Beam Global (BEEM): Free Stock Analysis Report Arcimoto, Inc. (FUV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Home Depot Q2 Preview: Can Shares Uphold Recent Strength?

Home Depot shares have tacked on a rock-solid 7% over the last three months, outperforming the S&P 500 by a fair margin. The Zacks Building Products – Retail Industry has been strong over the last month, gaining nearly 10% and outperforming the S&P 500. Still, the industry is down a deep 22% year-to-date. Below is a table illustrating the industry’s performance vs. the S&P 500 over several timeframes.Image Source: Zacks Investment ResearchA titan in the industry, Home Depot HD, is on deck to reveal Q2 earnings before market open on Tuesday, August 16th.Home Depot is the world’s largest home improvement specialty retailer, offering a diverse range of branded and proprietary home improvement items, building materials, lawn and garden products, décor products, and related services.How does the company shape up heading into its quarterly release? Let’s take a closer glance.Share Performance & ValuationHD shares have tumbled year-to-date, declining more than 20% in value and vastly underperforming the S&P 500.Image Source: Zacks Investment ResearchHowever, Home Depot shares have tacked on a rock-solid 7% over the last three months, outperforming the S&P 500 by a fair margin.Image Source: Zacks Investment ResearchHome Depot’s forward earnings multiple resides nicely at 18.9X, well below its five-year median of 21.9X but representing a slight 15% premium relative to its Zacks Industry.HD carries a Style Score of a B for Value.Image Source: Zacks Investment ResearchQuarterly EstimatesAnalysts have been primarily bullish for the quarter to be reported, with two positive estimate revisions hitting the tape over the last 60 days. In addition, the Zacks Consensus EPS Estimate of $4.95 represents a rock-solid 9.3% uptick in quarterly earnings year-over-year.Image Source: Zacks Investment ResearchThe growth doesn’t stop there – Home Depot is forecasted to have generated a mighty $43.4 billion in revenue throughout the quarter, translating to year-over-year quarterly revenue growth of 5.4%.Quarterly Performance & Market ReactionsHome Depot has been on an impressive earnings streak, chaining together nine consecutive bottom-line beats. Just in its latest quarter, the company exceeded the Zacks Consensus EPS Estimate by a sizable 11.4%.Top-line results have also been remarkable – Home Depot has registered ten consecutive revenue beats. Below is a chart illustrating the company’s revenue on a quarterly basis.Image Source: Zacks Investment ResearchIt’s worth noting that the market hasn’t been impressed with the company’s quarterly results as of late, with shares moving downwards five times over its last six prints.Putting Everything TogetherHome Depot shares have outperformed the general market over the last three months but still reside deep in the red year-to-date.In addition, the company sports solid valuation levels, with shares trading well below their five-year median.Quarterly estimates reflect solid growth, and the company has consistently reported quarterly results above estimates. However, the market hasn’t reacted well as of late following the recent prints.Heading into the release, Home Depot HD carries a Zacks Rank #3 (Hold) with an Earnings ESP Score of 0.5%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Home Depot, Inc. (HD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

IQIYI, Inc. Sponsored ADR (IQ) Gains But Lags Market: What You Should Know

In the latest trading session, iQIYI, Inc. Sponsored ADR (IQ) closed at $3.92, marking a +1.03% move from the previous day. iQIYI, Inc. Sponsored ADR (IQ) closed at $3.92 in the latest trading session, marking a +1.03% move from the prior day. The stock lagged the S&P 500's daily gain of 1.73%. Meanwhile, the Dow gained 1.27%, and the Nasdaq, a tech-heavy index, added 0.28%.Coming into today, shares of the company had gained 4.86% in the past month. In that same time, the Consumer Discretionary sector gained 12.28%, while the S&P 500 gained 9.34%.iQIYI, Inc. Sponsored ADR will be looking to display strength as it nears its next earnings release, which is expected to be August 30, 2022. In that report, analysts expect iQIYI, Inc. Sponsored ADR to post earnings of -$0.05 per share. This would mark year-over-year growth of 81.48%. Meanwhile, our latest consensus estimate is calling for revenue of $1.02 billion, down 13.82% from the prior-year quarter.IQ's full-year Zacks Consensus Estimates are calling for earnings of -$0.16 per share and revenue of $4.47 billion. These results would represent year-over-year changes of +81.82% and -5.38%, respectively.Investors should also note any recent changes to analyst estimates for iQIYI, Inc. Sponsored ADR. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 17.95% higher. iQIYI, Inc. Sponsored ADR currently has a Zacks Rank of #2 (Buy).The Film and Television Production and Distribution industry is part of the Consumer Discretionary sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 30% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report iQIYI, Inc. Sponsored ADR (IQ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 13th, 2022Related News

Tsakos Energy (TNP) Stock Sinks As Market Gains: What You Should Know

Tsakos Energy (TNP) closed the most recent trading day at $14.07, moving -1.26% from the previous trading session. Tsakos Energy (TNP) closed at $14.07 in the latest trading session, marking a -1.26% move from the prior day. This change lagged the S&P 500's daily gain of 1.73%. At the same time, the Dow added 1.27%, and the tech-heavy Nasdaq gained 0.28%.Prior to today's trading, shares of the oil and gas shipping company had gained 53.39% over the past month. This has outpaced the Transportation sector's gain of 13.68% and the S&P 500's gain of 9.34% in that time.Investors will be hoping for strength from Tsakos Energy as it approaches its next earnings release. On that day, Tsakos Energy is projected to report earnings of $1.53 per share, which would represent year-over-year growth of 229.66%. Our most recent consensus estimate is calling for quarterly revenue of $163.51 million, up 84.03% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.43 per share and revenue of $600.09 million. These totals would mark changes of +183.9% and +72.42%, respectively, from last year.Any recent changes to analyst estimates for Tsakos Energy should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 5.48% higher. Tsakos Energy is currently sporting a Zacks Rank of #1 (Strong Buy).Digging into valuation, Tsakos Energy currently has a Forward P/E ratio of 3.22. This represents a discount compared to its industry's average Forward P/E of 3.64.The Transportation - Shipping industry is part of the Transportation sector. This industry currently has a Zacks Industry Rank of 46, which puts it in the top 19% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow TNP in the coming trading sessions, be sure to utilize Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tsakos Energy Navigation Ltd (TNP): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: ZACKSAug 13th, 2022Related News

Bull of the Day: TTM Technologies (TTMI)

Tech names are hot as the NASDAQ Composite has rallied dramatically off the lows. This rally has been wonderful for those of us fortunate to hold four-letter tickers. The NASDAQ Composite surged 20% off the lows, helping to push up stocks throughout the tech sector. Some very famous tech stocks are up over 20% over this period of time. While that might feel great now, it’s important to know that you are investing in stocks that have what it takes for the long-haul. One of the easiest ways to uncover those stocks is by leaning on the time-tested performance of our Zacks Rank.Stocks with the best Zacks Ranks, like today’s Bull of the Day TTM Technologies TTMI have great earnings trends which can help investors stay profitable over the long run. TTM Technologies engages in the manufacture and sale of printed circuit boards (PCBs) worldwide. The company operates in two segments, PCB and RF&S Components.Image Source: Zacks Investment ResearchThe stock is currently ranks as a Zacks Rank #1 (Strong Buy). The reason for the favorable ranking is the series of earnings estimate revisions coming from analysts. Over the last thirty days, three analysts have increased their estimates for this year and next year. The bullish move has sent up the current year Zacks Consensus Estimate from $1.27 to $1.61 while next year’s number is up from $1.45 to $1.70. The reflects earnings growth of 25.78% this year and 5.8% next year.That’s coming on revenue growth of 13.66% this year and 5.75% next year. As for valuation, the stock is only trading 10.1x earnings. That is richer than a very low industry average of 4.8x but well below the market’s 18.6x. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TTM Technologies, Inc. (TTMI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

Best Value Stocks to Buy for August 12th

VAC and UNM made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 12, 2022. Here are two stocks with buy rank and strong value characteristics for investors to consider today, August 12th:Marriott Vacations Worldwide Corporation VAC: This vacation company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.1% over the last 60 days.Marriot Vacations Worldwide Corporation Price and Consensus Marriot Vacations Worldwide Corporation price-consensus-chart | Marriot Vacations Worldwide Corporation QuoteMarriott Vacations has a price-to-earnings ratio (P/E) of 14.43, compared with 55.70 for the industry. The company possesses a Value Score of B.Marriot Vacations Worldwide Corporation PE Ratio (TTM) Marriot Vacations Worldwide Corporation pe-ratio-ttm | Marriot Vacations Worldwide Corporation QuoteUnum Group UNM: This financial protection benefit solutions company specializing in debts and loans carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.Unum Group Price and Consensus Unum Group price-consensus-chart | Unum Group QuoteUnum has a price-to-earnings ratio (P/E) of 6.78, compared with 18.62 for the S&P 500. The company possesses a Value Score of A.Unum Group PE Ratio (TTM) Unum Group pe-ratio-ttm | Unum Group Quote See the full list of top ranked stocks here. Learn more about the Value score and how it is calculated here. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Unum Group (UNM): Free Stock Analysis Report Marriot Vacations Worldwide Corporation (VAC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

Best Growth Stocks to Buy for August 12th

CSL, DK and EQNR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 12, 2022. Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, August 12th:Carlisle Companies Incorporated CSL: This operator of diversified manufacturer of engineered products carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.6% over the last 60 days.Carlisle Companies Incorporated Price and Consensus Carlisle Companies Incorporated price-consensus-chart | Carlisle Companies Incorporated QuoteCarlisle has a PEG ratio of 0.89 compared with 1.14 for the industry. The company possesses a Growth Score of B.Carlisle Companies Incorporated PEG Ratio (TTM) Carlisle Companies Incorporated peg-ratio-ttm | Carlisle Companies Incorporated QuoteDelek US Holdings, Inc. DK: This integrated downstream energy company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 67.8% over the last 60 days.Delek US Holdings, Inc. Price and Consensus Delek US Holdings, Inc. price-consensus-chart | Delek US Holdings, Inc. QuoteDelek has a PEG ratio of 0.17 compared with 0.43 for the industry. The company possesses a Growth Score of B.Delek US Holdings, Inc. PEG Ratio (TTM) Delek US Holdings, Inc. peg-ratio-ttm | Delek US Holdings, Inc. QuoteEquinor ASA EQNR: This explorer and producer of petroleum and related products carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.5% over the last 60 days.Equinor ASA Price and Consensus Equinor ASA price-consensus-chart | Equinor ASA QuoteEquinor has a PEG ratio of 0.12 compared with 0.43 for the industry. The company possesses a Growth Score of A.Equinor ASA PEG Ratio (TTM) Equinor ASA peg-ratio-ttm | Equinor ASA Quote See the full list of top ranked stocks here. Learn more about the Growth score and how it is calculated here. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Delek US Holdings, Inc. (DK): Free Stock Analysis Report Carlisle Companies Incorporated (CSL): Free Stock Analysis Report Equinor ASA (EQNR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

New Strong Sell Stocks for August 12th

DDS, LPX, and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2022. Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Dillard's, Inc. DDS is a large fashion retailing company. The Zacks Consensus Estimate for its current year earnings has been revised 1% downward over the last 60 days.Louisiana-Pacific Corporation LPX is a manufacturer of home-building products. The Zacks Consensus Estimate for its current year earnings has been revised 7.9% downward over the last 60 days.IMAX Corporation IMAX is an entertainment technology company. The Zacks Consensus Estimate for its current year earnings has been revised 40.4% downward over the last 60 days.View the entire Zacks Rank #5 List. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dillard's, Inc. (DDS): Free Stock Analysis Report LouisianaPacific Corporation (LPX): Free Stock Analysis Report IMAX Corporation (IMAX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

The Zacks Analyst Blog Highlights PepsiCo, Qualcomm, HSBC, Automatic Data Processing and Illumina

The Zacks Analyst Blog Highlights PepsiCo, Qualcomm, HSBC, Automatic Data Processing and Illumina.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

The Zacks Analyst Blog Highlights VAMO, DVLU, XMVM, DDIV and SPVM

The Zacks Analyst Blog Highlights VAMO, DVLU, XMVM, DDIV and SPVM.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

Zacks Industry Outlook Highlights Airbnb and Perion Networks

Zacks Industry Outlook Highlights Airbnb and Perion Networks.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

The Zacks Analyst Blog Highlights H&R Block, Chemed, Suncor Energy, Open Text and Essent Group

The Zacks Analyst Blog Highlights H&R Block, Chemed, Suncor Energy, Open Text and Essent Group.....»»

Category: topSource: ZACKSAug 12th, 2022Related News

Zacks.com featured highlights include AMN Healthcare Services, Encore Wire and Global Ship

Zacks.com featured highlights include AMN Healthcare Services, Encore Wire and Global Ship.....»»

Category: topSource: ZACKSAug 12th, 2022Related News